This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Here's Why You Should Retain LHC Group (LHCG) Stock Now
by Zacks Equity Research
LHC Group (LHCG) continues to benefit from broad array of services and inorganic expansion. However, intense competition remains a woe.
Scoop Up These 5 Promising Interest Coverage Ratio Stocks
by Sumit Singh
Interest expense has a direct bearing on the profits of a company and the company's creditworthiness depends on how effectively it meets its interest obligations.
Is Amedisys (AMED) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (AMED) Outperforming Other Medical Stocks This Year?
3 Reasons Growth Investors Will Love Amedisys (AMED)
by Zacks Equity Research
Amedisys (AMED) possesses solid growth attributes, which could help it handily outperform the market.
Amedisys (AMED) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
Amedisys (AMED) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Amedisys (AMED) Q4 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
Amedisys' (AMED) fourth-quarter earnings benefit from solid year-over-year growth in Medicare and non-Medicare revenues within Home Health.
Amedisys (AMED) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Amedisys (AMED) closed at $179.12 in the latest trading session, marking a +1.49% move from the prior day.
Looking for a Growth Stock? 3 Reasons Why Amedisys (AMED) is a Solid Choice
by Zacks Equity Research
Amedisys (AMED) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Zacks.com featured highlights include: Gibraltar Industries, Amedisys, Chevron, MDU Resources and Chemed
by Zacks Equity Research
Zacks.com featured highlights include: Gibraltar Industries, Amedisys, Chevron, MDU Resources and Chemed
Buy These 5 Low Leverage Stocks This Earnings Season
by Zacks Equity Research
With the Q4 reporting cycle gaining pace slowly, investors should look for stocks that are less debt-ridden compared to others instead of considering earnings growth only.
The Zacks Analyst Blog Highlights: Enphase Energy, Brookfield Business Partners, Amedisys, Pure Storage and Match Group
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Enphase Energy, Brookfield Business Partners, Amedisys, Pure Storage and Match Group
Year of the Rat Spells Good Times for Wall Street: 5 Picks
by Tirthankar Chakraborty
Historically, during the Year of the Rat, the S&P 500's performance has been slightly better than the than the index's overall average of 11.4%.
New Strong Buy Stocks for January 24th
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for today:
Has Amedisys (AMED) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (AMED) Outperforming Other Medical Stocks This Year?
The Zacks Analyst Blog Highlights: MagnaChip Semiconductor, Ichor, Chico's FAS, Amedisys and PBF Logistics
by Zacks Equity Research
The Zacks Analyst Blog Highlights: MagnaChip Semiconductor, Ichor, Chico's FAS, Amedisys and PBF Logistics
Zacks.com featured highlights include: SYNNEX, MagnaChip Semiconductor, Delta Air Lines, Amedisys and Forterra
by Zacks Equity Research
Zacks.com featured highlights include: SYNNEX, MagnaChip Semiconductor, Delta Air Lines, Amedisys and Forterra
5 Top Stocks That Popped in 2020 and Have Strong Upside Left
by Nalak Das
It seems that Wall Street bulls have no intention of taking a breather after completing the best year in the last six years.
Invest in These 5 Stocks With Solid Relative Price Strength
by Nilanjan Choudhury
Want to try an out-of-the-box approach to earn handsome returns? Tap these stocks with explosive relative price strength.
Elanco (ELAN) Surges: Stock Moves 5.3% Higher
by Zacks Equity Research
Elanco (ELAN) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
3 Reasons Growth Investors Will Love Amedisys (AMED)
by Zacks Equity Research
Amedisys (AMED) possesses solid growth attributes, which could help it handily outperform the market.
Invest in These 5 Low Leverage Stocks Before Q4 Earnings
by Zacks Equity Research
Companies displaying high earnings growth along with high leverage ratios should be avoided while making investment decisions. So, investors should select companies with low leverage.
Job Additions Top 2 Million Mark Again in 2019: 5 Winners
by Zacks Equity Research
In 2019, 2.1 million employees were added. Here are five stocks that can benefit the most from healthy job additions from the top-gaining sectors.
These 5 Stocks Boast Impressive Interest Coverage Ratio
by Sumit Singh
A company's creditworthiness depends on how effectively it meets interest obligations. One that is capable of generating earnings well above its interest expense can withstand financial hardships.
Amedisys (AMED) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
Amedisys (AMED) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Amedisys (AMED) Upgraded to Strong Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Amedisys (AMED) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.